SpringerProtocols: Abstract: 1. Overview of Vaccines

1. Overview of Vaccines

By: Gordon Ada²

Abstract

Full Text

Download PDF (1241K)

Most vaccines are designed as a prophylactic measure, that is, to stimulate the immune response so that on subsequent exposure to the particular infectious agent, the extent of infection in the vaccinated individual is so low that disease does not occur. There is also increasing interest in designing vaccines that may be effective as a therapeutic measure. There are two contrasting types of infectious processes.

Affiliation(s): (2) Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, Australia

Book Title: Vaccine Protocols

Series: Methods in Molecular Medicine | Volume: 4 | Pub. Date: May-20-1996 | Page Range: 1-16 | DOI: 10.1385/0-89603-334-1:1

Subject: Immunology

References

Download References

1.	Cadoz, M., Strady, A., Meigner, B., Taylor, J., Tartaglia, J., Paoletti, E., and Plotkin, S. (1992) Immunization with canarypox virus expressing rabies glycoprotein. Lancet 339, 1429–1432.

2.	Clark, H. F. and Offit, P. A. (1994) Rotavirus vaccines, in Vaccines, 2nd ed. (Plotkin, S. A. and Mortimer, E. A., eds.), Saunders, Philadelphia, pp. 809–822.

3.	Maassab, H. F., Shaw, M. W., and Heilman, C. A. (1994) Live influenza virus vaccine, in Vaccines, 2nd ed. (Plotkin, S. A. and Mortimer, E. A., eds.), Saunders, Philadelphia, pp. 781–801

4.	Levine, M. M. (1994) Typhoid fever vaccines, in Vaccines, 2nd ed. (Plotkin, S. A. and Mortimer, E. A., eds.), Saunders, Philadelphia, pp. 597–634.

5.	Tartaglia, J., Perkus, M. E., and Taylor, J. (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217–232.

6.	Daniel, M. D, Kirchhoff, F., Czajak, S. C., Sehgal, P. K, and Desrosiers, R. C. (1992) Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938–1940.

7.	Mortimer, E. A. (1994) Pertussis vaccine, in Vaccines, 2nd ed. (Plotkin, S. A. and Mortimer, E. A., eds.), Saunders, Philadelphia, pp. 91–136.

8.	Hilleman, M. R. (1992) Vaccine perspectives from the vantage of hepatitis B. Vaccwe Res. 1, 1–15.

9.	Egea, E, Iglesias, A, Salazar, M, Morimoto, C., Kruskall, M. S., Awdeh, Z., Schlossman, S. F, Alper, C. A, and Yunis, E. J. (1991) The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J. Exp. Med. 173, 531–542

10.	Langmuir, I. D., Bregman, D. J., Kurland, L. D., Nathanson, N., and Victor, M. (1984) An epidemiological and clinical evaluation of Guillain-Barre syndrome reported in association with the administration of swine influenza vaccine. J. Epidemiol. 119, 841–879.

11.	Stratton, K. R., Howe, C. J., and Johnston, R. B. (1994) Adverse events associated with childhood vaccines. Evidence bearing on causality. Institute of Medicine, National Academy Press, Washington, pp. 1–464.

12.	Galaska, A M., Lauer, B. A, Henderson, R. H., and Keja, J. (1984) Indications and contraindications for vaccines used in the expanded programme of immunization. Bull. WHO 62, 357–366.

13.	Halsey, N. A. (1993) Increased mortality following high titer measles vaccines: too much of a good thing. Pedia. Infect. Dis. 12, 462–465.

14.	Kapikian, A. Z., Mitchell, R H., and Chanock, R. M. (1969) An epidemiological study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with inactivated RS virus vaccine. Am. J, Epidemiol. 89, 405–421.

15.	Expanded Programme on Immunization. Certification of poliomyelitis eradicationthe Americas, 1944. (1994) Weekly Epidemiological Record 69, 293–295

16.	Fenner, F. (1984) Viral vectors for vaccines, in New Approaches for Vaccine Development (Bell, R and Torrigiani, G, eds.), Schwabe, Basel, pp. 187–192.

17.	WHO Consultative Group on Poliomyelitis Vaccines. (1984) Report to World Health Organization, Geneva.

18.	Measles elimination by the year 2000! (1994) EPI Newsletter, Pan American Health Organization, Washington. 16, 1–2

19.	Douglas, R. G. (1993) The children’s vaccine initiative-will it work? J Inj. Dis 168, 269–274.

20.	Tam, J. P (1988) Synthetic peptide vaccine design: synthesis and properties of a high density multiple antigenic peptide system. Proc. Natl. Acad. Sci. USA 85, 5409–5413.

21.	Pruksakorn, S., Currie, B., Brandt, E., Martin, D., Galbraith, A, Phornphutkul, C., Hunsakunachai, S., Manmontri, A., and Good, M. F (1994) Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci. Lancet 344, 639–642.

22.	Kaumaya, P. T. P, Berndt, K. D., Herdorn, D. B., Trewhella, J., Kezdy, F. J., and Goldberg, E. (1990) Synthesis and biochemical characterization of engineered topographic immunogenic determinants with topology Biochemistry 29, 13–23

23.	Ada, G. L. (1993) Vaccines, in Fundamental Immunology, 3rd ed. (Paul, W. E., ed.), Raven, New York, pp 1309–1352.

24.	Ramsay, A. J., Husband, A. J., Ramshaw, I. A., Bao, S., Mattaei, K. I, Koehler, G., and Kopf, M. (1994) The role of interleukin-6 in mucosal IgA antibody responses in vivo Science 264, 561–563

25.	Schodel, F., Aguado, M.-T., and Lambert, P.-H (1994) Introduction: nucleic acid vaccines. Plus other contributions. Vaccine 12, 1491–1550.

26.	Leung, K. N. and Ada, G. L (1982) Different functions of subsets of effector T-cells in murine influenza virus infection. Cell Immunol. 67, 312–324.

27.	Larson, H. S., Russell, R. G., and Rouse, B. Y (1983) Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes Infect Immunol 41, 197–204.

28.	Jackson, D. C., Ada, G. L., and Tha Lha, R. (1976) Cytotoxic T cells recoginze very early, minor changes in ectromelia virus-infected target cells. Aust J Exp Biol Med. Sci. 54, 349–363

29.	Zinkernagel, R. M and Althage, A. (1977) Anti-viral protection by virus-immune cytotoxic T cells: infected targeT-cells are lysed before infectious virus progeny is assembled. J. Exp Med 145, 644–651

30.	Geisow, M. J (1991) Unravelling the mysteries of molecular audit: MHC class I restriction. Tibtech 9, 403–404.

31.	Ada, G. (1994) Twenty years into the saga of MHC-restriction. Immunol. Cell Blol. 72, 447–454.

32.	Taylor, G. (1994) The role of antibody in controlling and/or clearing virus infections, in Strategies in Vaccine Design (Ada, G. L, ed.), Landes, Austin, TX, pp. 17–34.

33.	Griffin, D. E., Levine, B., Tyor, W. B., and Irani, D N. (1992) The immune response in viral encephalitis. Semin Immunol. 4, 111–119.

34.	Ramshaw, I., Ruby, J., Ramsay, A., Ada, G., and Karupiah, G. (1992) Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo. Immunol. Rev. 127, 157–182.

35.	Ada, G. L. (1990) The immune response to antigens: the immunological principles of vaccination. Lancet 335, 523–526

36.	Sharma, D. P., Ramsay, A. J., and Ramshaw, I. A. (1995) Interleukin 4 expression enhances the pathogenicity of vaccinia virus and suppresses cytotoxic T lymphocyte responses. J. Exp. Med. submitted.

37.	Afonso, L. C. C., Scharton, T. M., Vieira, L. Q., Wysocka, M, Trinchieri, G., and Scott, P(1994) The adJuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263, 235–237

38.	Cooper, P. D. (1994) The selective induction of different immune responses by vaccine adjuvants, in Strategies in Vaccine Design (Ada, G. L., ed.), Landes, Austin, TX, pp. 129–158.

39.	Ada, G. L. (1995) The development of new vaccines, in Vaccination and World Health (Cutts, F and Smith, P. G., eds.), Wiley, in press.

40.	Gautam, A. M. and Glynn, P. (1990) Competition between foreign and self proteins in antigen presentation. Ovalbumin can inhibit activation of myelin basic protein-specific T-cells J.Immunol. 144, 1177–1180.

41.	Graham, B. S., Matthews, T. J., Belshe, R. B., Clements, M. L., Dolin, R., and Wright, P. F. (1993) Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp l60 recombinant vaccinia and boosting with rgp160 in vaccinia naive adults. J. Infect. Dis. 167, 533–537.

42.	El-Daher, N., Keefer, M. C, Reichman, R. C., Dolin, R., and Roberts, N. S. (1993) Persisting immunodefictiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. J Infect Dis. 168, 306–313

43.	Plotkin, S. A. and Mortimer, E. A. (eds.) (1994) Vaccines. W B. Saunders, Philadelphia.

Comments (Loading...)

Post comment/View all comments